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Abstract
Classical approaches to estimate vaccine efficacy are based on the assumption that a person’s risk of infection does not
depend on the infection status of others. This assumption is untenable for infectious disease data where such dependencies
abound. We present a novel approach to estimating vaccine efficacy in a Bayesian framework using disease transmission
models. The methodology is applied to outbreaks of mumps in primary schools in the Netherlands. The total study
population consisted of 2,493 children in ten primary schools, of which 510 (20%) were known to have been infected, and
832 (33%) had unknown infection status. The apparent vaccination coverage ranged from 12% to 93%, and the apparent
infection attack rate varied from 1% to 76%. Our analyses show that vaccination reduces the probability of infection per
contact substantially but not perfectly (VE^S = 0.933; 95CrI: 0.908–0.954). Mumps virus appears to be moderately
transmissible in the school setting, with each case yielding an estimated 2.5 secondary cases in an unvaccinated population
(R^0 = 2.49; 95%CrI: 2.36–2.63), resulting in moderate estimates of the critical vaccination coverage (64.2%; 95%CrI: 61.7–
66.7%). The indirect benefits of vaccination are highest in populations with vaccination coverage just below the critical
vaccination coverage. In these populations, it is estimated that almost two infections can be prevented per vaccination. We
discuss the implications for the optimal control of mumps in heterogeneously vaccinated populations.
Citation: van Boven M, Ruijs WLM, Wallinga J, O’Neill PD, Hahne´ S (2013) Estimation of Vaccine Efficacy and Critical Vaccination Coverage in Partially Observed
Outbreaks. PLoS Comput Biol 9(5): e1003061. doi:10.1371/journal.pcbi.1003061
Editor: Neil Ferguson, Imperial College London, United Kingdom
Received October 29, 2012; Accepted March 28, 2013; Published May 2, 2013
Copyright:  2013 van Boven et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Funding was provided by the Dutch Ministry of Health, Welfare and Sport, and the Netherlands Organisation for Health Research and Development
(grant 125050004). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: michiel.van.boven@rivm.nl
Introduction
Mass vaccination programs for childhood diseases have been
highly successful in reducing the incidence and public health
impact of the targeted diseases. Nevertheless, with the exception of
smallpox, eradication has not been achieved, and outbreaks
continue to occur even in highly vaccinated populations [1–4]. A
prominent example is that of mumps, which has re-emerged in the
past decade in highly vaccinated populations throughout the world
[5–7]. The question arises as to whether this re-emergence is due
to current vaccines becoming less effective, or to reduced vaccine
coverage which allows the virus to spread in partially vaccinated
populations [8].
In the Netherlands, large outbreaks of mumps genotypes D and
G have occurred in recent years [9–11]. Since 1987, a combined
MMR (measles-mumps-rubella) vaccine containing live attenuated
virus is routinely given at 14 months and 9 years of age.
Vaccination coverage has been high ever since introduction of the
vaccine in 1987 (90–95%). Nevertheless, there are municipalities
in which vaccination coverage is substantially lower [12,13].
To determine whether the outbreaks of mumps are the result of
low vaccination coverage or insufficient protection conferred by
the vaccine, we estimate vaccine efficacy using outbreak data from
ten primary schools in the Netherlands [9,11]. The total number
of children included in our study is 2,493, of whom 510 had a
reported mumps infection. Vaccination coverage in these schools
ranged from 12%–93%, and infection attack rates ranged from
4% to 76%, with highest attack rates occurring in schools with the
lowest vaccination coverage and lowest attack rates in schools with
high vaccination coverage (Table 1). Notably, the attack rates in
unvaccinated individuals varied from more than 80% in schools
with low vaccination coverage (,15%) to lower than 25% in
schools with high vaccination coverage ($75%), indicating
substantial differences in the infection pressure between schools.
Classical methods to estimate vaccine efficacy from outbreak
data compare the infection attack rates in the vaccinated versus
unvaccinated groups (i.e. the cohort method) [14,15]. This
method, however, has significant drawbacks. First, it is not
straightforward to take account of missing data on vaccination and
infection status. This is unfortunate as outbreak data are almost
never complete, and judicious choices will have to be made to
avoid introducing systematic bias in the parameter estimates. Even
more importantly, the cohort method fails to acknowledge that the
probability of infection of an individual is dependent on the
number of infections in the population, i.e. on the infection status
of others.
To take account of the dependencies between individuals that
arise naturally in infectious disease outbreaks we base the statistical
analyses on a Bayesian inferential framework using infectious
disease transmission models. In this framework, missing vaccina-
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tion and infection information is imputed in a consistent manner,
thereby making efficient use of the available information, and
enabling precise estimation of vaccine efficacy and the critical
vaccination coverage needed to prevent epidemic outbreaks
[16,17]. The basis of our statistical analyses is the contact process
that specifies how often and with which person-types each person
makes infectious contacts, i.e. contacts that are sufficient for
transmission if the sender is infected and the receiver as yet
uninfected [18–20]. The contact process specifies a directed graph,
of which the connected component with the initial infective as the
root determines which individuals are ultimately infected. Estima-
tion of the epidemiological parameters (basic reproduction
number, vaccine efficacy) is based on the likelihood of directed
graphs that are compatible with the data.
The analyses reveal that mumps vaccine effectively prevents
infection, and that herd immunity against mumps is achieved with
moderate vaccination coverages. We argue that resource-limited
catch-up vaccination efforts should be focused at communities
with intermediate vaccination coverages, thereby maximizing both
the direct and indirect benefits of vaccination.
Results
Vaccine efficacy and the critical vaccination coverage
Our baseline scenario assumes a common transmissibility and
vaccine efficacy across schools. The analysis indicates that mumps
is moderately transmissible (R^0 =2.49; 95%CrI: 2.36–2.63), and
that the vaccine reduces the probability of transmission by more
than 90% per contact that would have resulted in transmission to
an unvaccinated person (VE^S =0.933; 95CrI: 0.908–
0.954)(Figure 1). The differences between the apparent and
estimated vaccination coverages and attack rates are small (,2%
and ,5%, respectively; Tables 1–2).
We use estimates of transmissibility and vaccine efficacy to
obtain estimates of the critical vaccination coverage. The analyses
yield an estimated critical vaccination coverage of 0.642 (95%CrI:
0.617–0.666), indicating that herd immunity in the school setting
can be obtained with moderate vaccination coverages. Estimates
of transmissibility and vaccine efficacy are used to obtain an
estimate of the number of infections prevented per vaccination.
This number is highest for vaccination coverages just below the
critical vaccination coverage, as at these values the slope of attack
rate versus vaccination coverage is steepest (Figure 2). The number
of infections prevented per vaccination near the threshold
coverage is well approximated (using a Taylor series expansion)
by2VES . Hence, it is expected that the (direct and indirect)
benefits of vaccination are such that 2VE^S&1:9 infections can be
prevented per vaccination if the initial vaccination coverage is
just below the threshold value, which is estimated by
VE^{1S 1{R^
{1
0
 
~0:64.
Schools with low versus high vaccination coverage
Schools in our study population span a large range of possible
vaccination coverages, and it is of interest to evaluate the
consistency of the estimates of vaccine efficacy and pathogen
transmissibility. Figure 2 shows the relation between vaccination
coverage and infection attack rate in the ten schools, together with
Table 1. Summary statistics of the study population.
number of
persons
number
infected
vaccination
coverage
attack rate in
unvaccinated persons
attack rate in
vaccinated persons
overall
attack rate
all schools 2493 510–1342 0.62* 0.68 (485/709) 0.03 (25/952) 0.31
school 1 432 205–369 0.12 0.86 (204/237) 0.03 (1/31) 0.76
school 2 338 135–289 0.13 0.82 (131/160) 0.17 (4/24) 0.73
school 3 259 68–159 0.42 0.72 (68/94) 0 (0/74) 0.40
school 4 184 40–70 0.54 0.53 (37/70) 0.04 (3/84) 0.26
school 5 130 13–33 0.75 0.46 (13/28) 0 (0/82) 0.12
school 6 263 28–171 0.76 0.70 (19/27) 0.10 (9/93) 0.23
school 7 194 6–43 0.78 0.19 (6/31) 0 (0/126) 0.04
school 8 227 3–27 0.79 0.05 (2/41) 0.01 (1/162) 0.01
school 9 258 6–119 0.93 0.18 (2/11) 0.03 (4/134) 0.04
school 10 208 6–62 0.93 0.30 (3/10) 0.02 (3/142) 0.04
The column ‘number infected’ shows the possible range of actual infections, ranging from the number known to be infected to the sum of this number and the number
of persons with unknown infection status. Vaccination coverages and attack rates are calculated using persons with known vaccination status (vaccination coverage),
and known vaccination and infection status (attack rates). See Tables S1, S2 for the complete data.
*: averaged over schools.
doi:10.1371/journal.pcbi.1003061.t001
Author Summary
Less than two decades ago, it was generally believed that
in developed countries infectious diseases such as measles,
mumps, and pertussis were under firm control via
vaccination. Nowadays, it is increasingly recognized that
this picture has been overly optimistic. A central question
is whether recurrent disease outbreaks are caused by
vaccination coverage having dropped below safe levels, or
by vaccines having become less effective. To answer this
question, the authors study outbreaks of mumps in
primary schools in the Netherlands. Using disease trans-
mission models, the authors estimate vaccine efficacy and
the critical vaccination coverage needed to prevent large
outbreaks. The analyses show that the vaccine has been
highly effective in preventing infection, but that vaccina-
tion coverage has been insufficient in some schools. The
authors argue that catch-up vaccination campaigns aimed
at populations with intermediate vaccination coverage will
be most efficient, as these would maximize the (direct and
indirect) benefits of vaccination.
Mumps Vaccine Efficacy
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the theoretical relation between vaccination coverage and attack
rate in a large population, and simulations of a finite population.
Overall, the correspondence between the observed and simulated
data is excellent for schools with low vaccination coverage and
high attack rates, while there is a tendency for higher attack rates
than expected in schools with high vaccination coverage and a
small number of infections.
To investigate the information contained in the data by school
we perform analyses in which each school is equipped with its own
transmissibility and vaccine efficacy. It appears that precise
estimates of transmissibility and vaccine efficacy can be obtained
in schools with high attack rates (schools 1–4), but not in schools
with only a handful of infections (schools 7–10). In fact, in schools
with less than 10 confirmed infections credible intervals of the
reproduction number range from well below 1 to more than 3,
while vaccine efficacy estimates can range from less than 0.20
(schools 8–10) to almost 1 (schools 7–10; Table 3, Figure 3).
Further, the analyses show that in schools with high attack rates
(schools 1–4) the parameter estimates are quite close to those of the
baseline scenario, indicating that estimates of transmissibility and
vaccine efficacy in the baseline scenario are dominated by schools
with large numbers of infections and low vaccination coverages.
Estimation of vaccine efficacy by the cohort method
In comparison with our estimates of vaccine efficacy as the
reduction in the probability of infection (Table 3), estimates of
vaccine efficacy by the cohort method tend to be somewhat lower
in schools with low vaccination coverage and high infection attack
Figure 1. Posterior distributions of the basic reproduction number and vaccine efficacy (A) and vaccination coverages and attack
rates (B) when assuming common parameters across schools (baseline scenario). The median of the basic reproduction number is 2.49
(95% CrI: 2.36–2.63) and the median of vaccine efficacy is 0.933 (95CrI: 0.908–0.954). The estimated critical vaccination coverage is 0.642 (95% CrI:
0.617–0.666).
doi:10.1371/journal.pcbi.1003061.g001
Table 2. Estimates of vaccination coverage and attack rate per school when assuming common epidemiological parameters
across schools (baseline scenario).
unvaccinated vaccinated vaccination coverage attack rate
total infected total infected
school 1 382 (372–389) 327 (315–337) 50 (43–59) 3 (1–6) 0.12 (0.10–0.14) 0.77 (0.74–0.79)
school 2 293 (286–301) 243 (232–256) 45 (37–52) 6 (4–11) 0.13 (0.11–0.15) 0.74 (0.70–0.78)
school 3 150 (141–158) 110 (101–119) 109 (101–117) 3 (0–8) 0.42 (0.39–0.45) 0.44 (0.41–0.47)
school 4 84 (79–90) 45 (41–50) 100 (94–104) 4 (3–6) 0.53 (0.51–0.56) 0.27 (0.24–0.30)
school 5 33 (30–37) 15 (13–18) 97 (93–100) 0 (0–2) 0.75 (0.72–0.77) 0.12 (0.10–0.15)
school 6 67 (59–76) 50 (42–59) 196 (187–204) 20 (14–27) 0.75 (0.71–0.78) 0.27 (0.23–0.30)
school 7 42 (38–46) 10 (7–13) 152 (148–156) 0 (0–3) 0.78 (0.76–0.80) 0.05 (0.04–0.07)
school 8 48 (45–52) 3 (2–5) 179 (175–182) 1 (1–2) 0.79 (0.77–0.80) 0.02 (0.01–0.03)
school 9 18 (13–25) 6 (3–11) 240 (233–245) 11 (7–16) 0.93 (0.90–0.95) 0.07 (0.05–0.09)
school 10 13 (10–17) 4 (3–7) 195 (191–198) 5 (3–8) 0.94 (0.92–0.95) 0.05 (0.03–0.06)
Estimates are represented by posterior medians with 95% credible intervals.
doi:10.1371/journal.pcbi.1003061.t002
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rates (schools 1–4; Table 4, Table S3). Moreover, in these schools
credible intervals tend to be slightly broader when using the cohort
method. The most conspicuous difference, however, is that in
populations with high vaccination coverage (schools 7–10), vaccine
efficacy is sometimes estimated with fair precision when using the
cohort method, even though the number of infections is very small
(#6).
Discussion
Our analyses have shown that mumps is moderately transmis-
sible in the setting of primary schools, and that the vaccine used in
these populations is highly effective in preventing infection. These
results are largely in line with earlier studies [5,6], but contrast
with a recent study that suggested that outbreaks of mumps in
populations with large-scale vaccination programs may be due to
the vaccine having become less effective in preventing infection
[4]. The younger average age of our study population and the fact
that these outbreaks have been caused by viruses of different
genotypes (genotype D versus genotype G) may help explain these
contrasting findings. Since genotype D viruses are genetically
distant from the current vaccine virus (Jeryl Lynn strain, genotype
A) our results indicate that the Jeryl Lynn-based vaccine is highly
effective in curbing transmission to vaccinated persons, even if
genetic differences between the vaccine and outbreaks strains are
substantial [8].
Estimates of the transmissbility of mumps are most precise in
schools 1–4, i.e. in schools with low vaccination coverage and large
numbers of infections. In these schools, the basic reproduction
number is estimated at 2.5, 2.3, 2.8, and 2.5, with credible
intervals ranging from 1.9 to 3.2. Vaccine efficacy, on the other
hand, is estimated most precisely in schools 1, 3, 4, and 5 (Table 3,
Figure 3). In these schools, estimates of vaccine efficacy are 0.97,
0.99, 0.94, and 0.98, with credible intervals ranging from 0.84 to
1. These schools have low vaccination coverage and high levels of
exposure (i.e. high attack rates) but still more than 30 vaccinated
persons. In school 2 the exposure level has been high but the
number of vaccinated persons is too small for precise estimation of
vaccine efficacy. In schools with high coverage, vaccine efficacy
cannot be estimated with any precision, as in these schools it is
uncertain whether escape from infection is caused by the vaccine
or by a lack of exposure.
The schools included in this study differ greatly with respect to
vaccination coverages (range: 12%–93%) and infection attack
rates (range: 4%–76%). Nevertheless, estimates of vaccine efficacy
are remarkably consistent across schools (Table 3, Figure 3). In
fact, only in schools with just a handful of infections (#6) (schools
8–10) does the estimated vaccine efficacy drop below 0.88. In these
schools, credible intervals of vaccine efficacy are wide, and
estimates are less determined by the information contained in the
data than by the prior distribution of vaccine efficacy. This is also
the reason that estimates of vaccine efficacy in the baseline
scenario are dominated by schools with low vaccination coverages
and high attack rates, as these schools contain much more
information than schools with high vaccination coverages and low
infection attack rates (Figure 2).
Schools in our study were included based on confirmed mumps
infections. It is therefore possible that large outbreaks are more
likely to be detected and included than small outbreaks. In other
Figure 2. Relation between vaccination coverage and overall
attack rate in the baseline scenario. The figure shows the medians
of the posterior vaccination coverages versus posterior attack rates in
the ten schools (blue dots), the deterministic final size attack rate using
the posterior medians of the basic reproduction number and vaccine
efficacy (dotted line), and the results of simulations in populations of
size 200 using samples from the posterior distributions of the basic
reproduction number and vaccine efficacy (black line: median; grey
area: 2.5%–97.5% percentiles). See text for details.
doi:10.1371/journal.pcbi.1003061.g002
Table 3. Overview of the analyses per school (cf. Figure 3).
basic reproduction number (R
^
0) vaccine efficacy (VE
^
S) critical vaccination coverage (q
^
C)
school 1 2.5 (2.3–2.7) 0.97 (0.91–1.0) 0.63 (0.59–0.67)
school 2 2.3 (2.1–2.5) 0.87 (0.67–0.96) 0.65 (0.57–0.80)
school 3 2.8 (2.4–3.3) 0.99 (0.96–1.0) 0.66 (0.60–0.70)
school 4 2.5 (1.9–3.2) 0.94 (0.84–0.98) 0.64 (0.51–0.74)
school 5 3.6 (2.1–6.0) 0.98 (0.89–1.0) 0.74 (0.54–0.85)
school 6 3.0 (2.2–3.9) 0.88 (0.78–0.94) 0.76 (0.66–0.83)
school 7 1.9 (0.73–3.8) 0.95 (0.67–1.0) 0.51 (0–0.77)
school 8 1.1 (0.25–3.5) 0.67 (0.06–0.96) 0.10 (0–1)
school 9 0.96 (0.31–2.9) 0.67 (0.08–0.92) 0 (0–0.74)
school 10 1.6 (0.40–4.5) 0.80 (0.16–0.96) 0.46 (0–0.85)
The table shows the estimates of the basic reproduction number, vaccine efficacy, and critical vaccination coverage. Estimates are represented by posterior medians
with 95% credible intervals.
doi:10.1371/journal.pcbi.1003061.t003
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words, it is conceivable that the inclusion process systematically
favours inclusion of schools with uncharacteristically high attack
rates, thereby leading to selection bias. For schools with low
vaccination coverage (and high attack rates) this is arguably not a
problem as variation in outbreak sizes is expected to be minor,
given the sizes of the schools included (Figure 2). For schools with
high vaccination coverage, however, selection bias may well have
played a role, and may explain the relatively high attack rates in
some of these schools (school 6 and to a lesser extend schools 9–10)
(Figure 2). Fortunately, one could argue that our statistical
methodology provides a natural weighting of schools, in which
schools with small number of infections have lower weight than
schools with high number of infections. If specific details were
available on the inclusion process, one could envisage extension of
the analyses in which the selection process is modelled explicitly.
This, however, would introduce more model options, additional
parameters to be estimated, and would certainly lead to a more
complicated analysis.
We have assumed throughout that infections outside the school
played a marginal role. Again, this assumption is probably less
problematic in schools with low vaccination coverage and high
infection attack rates than in schools with high vaccination
coverage and lower attack rates, as variation in the expected
number of infections is expected to be small in schools with low
vaccination coverage. Moreover, there was no sustained commu-
nity transmission during the study period, suggesting that the
impact of infection outside the schools may have been small.
Nevertheless, it would be interesting to extend the current
analyses, e.g., along the lines of [21,22] by inclusion of other
major transmission settings.
Classical estimates of mumps transmissibility have been based
on the mean age at infection in the pre-vaccination era ([23] and
references therein), or on seroprevalence data from the pre-
vaccination era [24,25]. These analyses yielded estimates of the
basic reproduction number in fully unvaccinated populations that
are substantially higher (,7–20) than our estimates (,2–3). It
should be noted that these population-based estimates cannot
directly be translated to our school-based estimates. Still, should
those early estimates be indicative of the current transmissibility of
mumps at the population level, then not only are schools an
important transmission route but other settings also have the
potential to contribute significantly to overall transmission. Again,
to assess the contribution of different settings to the overall
Table 4. Estimates of vaccine efficacy by the cohort method,
i.e. as 1 minus the relative risk of infection in vaccinated
versus unvaccinated persons (1{RR).
vaccine efficacy (12R
^
R )
school 1 0.93 (0.81–0.99)
school 2 0.76 (0.56–0.92)
school 3 0.98 (0.93–1.0)
school 4 0.91 (0.80–0.98)
school 5 0.97 (0.90–1.0)
school 6 0.84 (0.73–0.93)
school 7 0.96 (0.83–1.0)
school 8 0.75 (0.0–0.98)
school 9 0.78 (0.25–0.96)
school 10 0.90 (0.68–0.98)
Estimates are represented by posterior medians with 95% credible intervals. See
text for details.
doi:10.1371/journal.pcbi.1003061.t004
Figure 3. Estimated reproduction numbers (top, blue dots) and vaccine efficacies (bottom, gray dots) per school, with associated
95% credible intervals (cf. Table 3). Note that estimated vaccine efficacy is consistently high in schools with high exposure (schools 1–6), but
cannot be estimated with any precision in schools with low exposure (schools 8–10).
doi:10.1371/journal.pcbi.1003061.g003
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transmission dynamics, it would be desirable to extend the current
studies beyond the school setting, by including household
information and, in the specific case of this study, information
on the churches attended by the participants [9]. This, however, is
only possible if detailed information were available on these
settings, not only with respect to their composition but also with
respect to vaccination and infection status of a sizeable part of the
population.
Vaccine efficacy and transmissibility together determine the
critical vaccination coverage needed to prevent epidemic out-
breaks. In our study, estimates of the critical vaccination coverage
are 64% (95%CrI: 62%–67%) in the baseline scenario, and range
from 63% (95%CrI: 58%–68%; school 1) to 76% (95%CrI: 66%–
83%; school 6) in schools with more than 10 confirmed infections
(schools 1–6). This indicates that the critical vaccination coverage
does not need to be as high as suggested by early population-based
estimates, which are in the range of 86%–95%.
In none of the analyses presented here have we made a
distinction between children who had been vaccinated once and
those that had been vaccinated twice. This was done because
preliminary analyses and previous results [9,11] could not find any
evidence for differences in vaccine efficacy between the two
groups. In view of the data this is not unexpected, as the total
number of infections in vaccinated children was small, and as
attack rates in the two subpopulations were identical (15 infections
among the 582 children who had been vaccinated once; 10
infections among the 370 who had been vaccinated twice). The
fact that attack rates were identical is somewhat surprising, as one
could have expected more infections in the group that had been
vaccinated only once, more than five years ago. For completeness,
we have presented the full data in Table S2.
Further, in our analyses we assume that the vaccine works by
reducing the probability of transmission (i.e. we assume a leaky
vaccine), rather than by providing all-or-nothing immunity. This
was done for simplicity, and since the current data do not allow us
to distinguish between the different workings of the vaccine. If
additional data was available, e.g., on the pre-outbreak antibody
titres, one could consider extension of the method by using pre-
outbreak antibody titres as an indicator for the ‘level of immunity’,
and use this indicator to estimate how the level of pre-existing
immunity relates to the probability of infection. In most situations,
however, such information will be hard to get, as this would
necessitate a large prospective study.
Our definition of vaccine efficacy has a clear-cut biological
interpretation (reduction of the probability of infection per
contact). This makes it possible to meaningfully average over
populations with varying vaccination coverages and exposure
levels, and also to extrapolate beyond the study population. This
contrasts with traditional estimates of vaccine efficacy that are
based on a comparison of attack rates in vaccinated and
unvaccinated individuals (the cohort method), or that simply use
the vaccination status of the infected individuals together with the
population vaccination coverage (the screening method) [14,26].
Vaccine efficacy estimated by these methods lack a clear biological
interpretation, and in essence assumes that a person’s risk of
infection is independent of whether or not others in the population
are infected. This makes interpretation of the estimates problem-
atic, and forbids estimation of the critical vaccination coverage
[15,27–29].
Even though our definition of vaccine efficacy differs funda-
mentally from vaccine efficacy measured by the cohort method,
the results are quantitatively in fair agreement with traditional
estimates, especially in populations with low vaccination
coverage and large number of infections (Table 3 versus
Table 4 and Table S3). In schools with high vaccination
coverage and small numbers of infections the reverse tends to be
true, and estimates of vaccine efficacy generally are both higher
and more precise when using the cohort method. For instance,
in school 10 there are 6 confirmed infections, and vaccine
efficacy is poorly estimated in our analysis (95%CrI: 0.16–0.96)
but with fair precision by the cohort method (95%CrI: 0.68–
0.98). This is arguably an artefact of the latter method’s
assumption that all 139 uninfected vaccinated persons have
been exposed to an infected person, thereby artificially
increasing the precision of the estimates of vaccine efficacy.
Our results point to strategies to efficiently allocate catch-up
vaccination efforts in heterogeneously vaccinated populations. No
additional vaccination is needed in schools with high vaccination
coverage (.75%, say) as these are already protected against
epidemic outbreaks affecting a large fraction of students. Similarly,
allocating vaccines to schools with low vaccination coverage
(,50%, say) is inefficient as it does not markedly reduce the
probability of infection for those who are not vaccinated, i.e. the
indirect benefits of vaccination are small in these populations. Our
analyses suggest that vaccination of populations in the range
between these two extremes is most efficient, and that in these
populations a single vaccination can potentially prevent almost
two infections. Of course, in practice other considerations, for
instance on ethical issues, communication, and cost-effectiveness
would also come into play.
Methods
Study design and data collection
In the Netherlands, several large outbreaks of mumps virus
(genotype D) occurred in 2007–2009. We collected data from
children attending primary schools with evidence of mumps virus
transmission (report of at least one laboratory confirmed mumps
case or more than one clinical mumps case) [9,11]. Children’s
parents were asked to fill out a questionnaire asking for
information on the child’s vaccination status and occurrence of
mumps. Individual data on vaccination status were also retrieved
from the national Dutch vaccination register. When these were not
available, we used the self-reported vaccination status (vaccinated/
unvaccinated). Children who were vaccinated more than twice
(one case), and who were reported to have had mumps before
September 2007 (three cases) were excluded. The study was
approved by the medical ethics committee of the University
Medical Centre Utrecht and the Radboud University Nijmegen
Medical Centre. The data are presented in Table 1 and Tables S1,
S2.
Estimation of vaccine efficacy in a disease transmission
framework
Model structure. The analyses are based on the distribution
of the number of persons infected in an outbreak [16–18].
Specifically, we use so-called final size distributions of a two-type
SEIR (susceptible-exposed-infectious-recovered) model in which
the two types represent unvaccinated and vaccinated persons.
In SEIR models, each individual in the population can either be
susceptible (i.e. healthy), exposed (infected but not able to infect
others), infective (infected and able to infect others) or recovered (not
infectious and now immune). We assume that infectious contacts are
made at the level of the school, and not at other organizational levels
(e.g., class, household, community). These assumptions seem
reasonable since there was no evidence of sustained community
transmission during the study period, while only limited information
was available on class structure within schools.
Mumps Vaccine Efficacy
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We focus on estimation of two key epidemiological quantities,
the basic reproduction number R0 which quantifies the transmis-
sibility of the pathogen, and vaccine efficacy VES which
determines the reduction in the probability of infection for those
who have been vaccinated. We use a Bayesian inferential
framework in which these parameters are estimated and the
missing information is imputed.
Throughout we assume that a pair of individuals makes contacts
at a rate that is inversely proportional to the school size N, thus
ensuring that each person makes an identical expected number
of contacts per unit of time. Specifically, whilst infective an
unvaccinated person makes infectious contacts with each
unvaccinated individual according to a Poisson process of
rate l
N
, and with each vaccinated individual according to a
Poisson process of rate 1{VESð Þ lN, where VES represents
vaccine efficacy for susceptibility [1]. All Poisson processes are
assumed mutually independent. Notice that vaccine efficacy as
defined here can be interpreted as the reduction in the
probability of infection for a contact that would have resulted
in infection if the contacted person was unvaccinated. Hence,
we have 0ƒVESƒ1 by definition.
Final size data alone do not allow us to estimate parameters with
respect to calendar time, but only relative to other model
parameters. To set a time-scale, and for simplicity, we therefore
assume that the infectious period (i.e. the time that an individual is
in the infective state) is fixed at length 1 time unit and set the basic
reproduction number R0equal to the contact rate parameter l. An
alternative possibility, which could also be incorporated into our
modelling and inference framework, is to assume that infectious
periods are exponentially distributed with mean 1, which yields a
geometric distribution for the number of contacts made by an
individual whilst they remain infective [30,31]. In practice, this
alternative choice of infectious period distribution rarely makes
any material difference to the results [18].
Our model contains two epidemiological parameters, namely
the basic reproduction number R0 determining overall trans-
missibility, and vaccine efficacyVES which quantifies the extent
to which vaccination reduces the probability of becoming
infected by a single contact. In a large population with
vaccination coverage q the reproduction number in the early
stages of an epidemic, Rq, takes a simple form, namely
Rq~R0 1{q VESð Þ [32]. The critical vaccination coverage qc
which makes major outbreaks highly improbable is found by
solving the above equation for Rq~1, yielding
qc~VE
{1
S 1{R
{1
0
 
:
This equation is used to estimate the critical vaccination
coverage directly from estimates of the basic reproduction
number and vaccine efficacy.
The parameters R0, VES , and q also determine outbreak size in
a large population through the final size equations
zU~1{exp { 1{qð ÞRUUzU{qRVUzVð Þand zV~1{exp { 1ðð
{qÞRUVzU{qRVVzV Þ, where zU and zV denote the fractions
infected in the unvaccinated and vaccinated groups, and Rij
(i,j[ U ,Vf g) represent the type-reproduction numbers [32]. In our
model we have R.U~R0 and R.V~ 1{VESð ÞR0.
The likelihood function. In a Bayesian framework the key
object of interest is the posterior density of the model parameters p
given data d, p p djð Þ. Using Bayes’ rule the posterior density can be
expressed as p p djð Þ!p d pjð Þp pð Þ, where p d pjð Þ is the likelihood
and p pð Þ the prior density of the parameters. In practical
applications, this formulation is of limited use because the
likelihood p d pjð Þ can be extremely complicated, even if no
infection or vaccination information is missing. We therefore
adopt an alternative approach in which attention is shifted to the
joint posterior density of the parameters of interest and random
directed graphs (digraphs) G which describe the potential
pathways of infection. Specifically, a given graph Gdescribes all
directed contacts made between individuals, some of which may
correspond to actual infections (e.g. a link from an infective to a
susceptible) while others may not (e.g. a link from a susceptible to
an infective). Knowledge of G, and the identity of the initially
infective individual(s), determines which individuals in the
population ultimately become infected, i.e. the final outcome. Full
details of this method are given in [18,19] and so we now recall the
salient points in our setting.
The augmented posterior density is given by
p p,G djð Þ!p d p,Gjð Þp G pjð Þp pð Þ,
where p d p,Gjð Þp G pjð Þ is the augmented likelihood, and p pð Þ is
the prior density of the parameters [18]. The (augmented)
likelihood contains two factors, of which the first indicates whether
a certain combination of parameters and digraphs is compatible
with the data, i.e. p d p,Gjð Þ~1 if the parameters and digraphs are
compatible with the data, and p d p,Gjð Þ~0 otherwise. The second
factor gives the likelihood of a certain infection graph conditional
on the values of the transmission parameters. For a single school
the likelihood of a digraph G given parameters p, p G pjð Þ, is given
by the product of the likelihoods of all infectious links and non-
links (i.e. the absence of an infectious link) in the set of infected
and potentially infected persons, times the product of all non-
links from infected persons to persons who were known to be
uninfected. Hence, in a school with n1 infected persons, n2
potentially infected persons, and n3 uninfected persons, p G pjð Þ
is given by the product of the probabilities of all
n1zn2ð Þ n1zn2{1ð Þ links and non-links in the set of infected
and potentially infected persons, times the product of the
probabilities of the non-links from persons that are infected in
the digraph to persons who are known to be uninfected. Since
there are at least n1 infected persons and n3 uninfected persons
the number of non-links to uninfected persons is at least n1n3. It
can be higher if some of the persons with unknown infection
status are infected, and reaches a maximum of n1zn2ð Þn3 if all
persons with unknown infection status are infected.
The above description can be made mathematically precise
[18,19]. If we denote by I the (unobserved) set of infected
individuals (of which there are at least n1 and at most n1zn2), by
I the set of individuals who are known to be infected together
with the individuals who may or may not have been infected, by J
the set of individuals who are known to be uninfected, by U (for
unvaccinated) and V (for vaccinated) the possible person types,
by t ið Þ[ U ,Vf g the type of an individual with label i, by pt ið Þt the
probability that there is a link from the individual with label i to
an individual of type t, by nit the number of links from
individual i to persons of type t, by Nt the number of individuals
of type t in I ( P
t[ U ,Vf g
Nt~n1zn2), and by Mt the number of
individuals of type t in J (
P
t[ U ,Vf g
Mt~n3), then the likelihood
p G pjð Þ is given by
p Gjpð Þ~
P
i[I
P
t[ U ,Vf g
p
nit
t ið Þt 1{pt ið Þt
 Nt{1 t ið Þ~tf g{nitxP
i[I
P
t[ U ,Vf g
1{pt ið Þt
 Mt :
ð1Þ
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Recall that we assume that the infectious periods are of fixed
duration. Together with our earlier assumption that contacts are
made according to mutually independent Poisson processes with
rates that are inversely proportional to school size, the infection
probabilities pst (s,t[ U ,Vf g) are given bypst~1{exp { RstN
 
,
where Rst are the type-specific reproduction numbers, Our
parameterization implies R.U~R0 and R.V~ 1{VESð ÞR0.
Scenarios and estimation. The parameter vector p contains
the epidemiological parameters R0 and VES , and the unknown
vaccination statuses. Throughout, the basic reproduction number
and vaccine efficacy are assigned uninformative uniform prior
distributions (0ƒVESv1 and R0w0). We further assume that the
probability that a person with unknown vaccination status is
vaccinated is given by the observed vaccination coverage of the
school in which the person resides (Table 2). We consider two
scenarios: One in which both R0 and VES are identical across
schools, and the other in which R0 and VES are estimated for each
school separately.
The posterior density is explored using a Markov chain Monte
Carlo method, whereby the missing vaccination statuses are
included as latent parameters [18–20]. Digraphs are updated by
adding and deleting edges at random from I. Specifically, we use
a birth-death construction for updating, in which infectious
contacts between any two persons that are (potentially) infected
are chosen uniformly at random [18–20]. The Metropolis-
Hastings acceptance probability of adding an infectious link to a
digraph G resulting in a digraph G0, is given by p G
0 Dpð Þ
p GDpð Þ
‘max{‘G
‘Gz1
,
where ‘max~ n1zn2ð Þ n1zn2{1ð Þ is the maximum number of
infectious contacts, and ‘G~
P
i[I
P
t[ U ,Vf g
nit the number of infec-
tious contacts in I. Likewise the acceptance probability of an
attempt to delete an edge is
p G0 Dpð Þ
p GDpð Þ
‘G
‘max{‘Gz1
, where it is understood
that digraphs that are not compatible with the data have zero
likelihood. Notice that, in contrast to earlier studies, the likelihood
ratio of two graphs differing by one link in general does not reduce
to the likelihood ratio of having an infectious contact at a
particular position versus not having an infectious contact at that
position [18–20]. In particular, it is possible that by adding or
deleting an infectious contact the number of infected persons
increases or decreases by more than one, because an addition or
deletion of an infectious contact could result in the addition or
deletion of a number of vertices to the connected component
which determines the final size. Hence, updating of the graphs
requires calculation of the full likelihood of the proposed graph,
which is a computationally expensive operation, resulting in long
runtimes if the number of infected persons is large.
The basic reproduction number and vaccine efficacy are
updated with a random-walk Metropolis algorithm using Gaussian
proposal distributions with standard deviations of 0.2–2 and 0.02–
0.2, respectively. Vaccination statuses are updated by flipping the
vaccination status of a randomly selected person with unknown
vaccination status [20]. The index case is assumed to be an
unvaccinated person.
Updating is performed in blocks, in the order 1) update the
value of the reproduction number, 2) update the value of vaccine
efficacy, 3) for each school update the vaccination status of a
randomly chosen person with missing vaccination information, 4)
for each school attempt to add an infectious contact, and 5) for
each school attempt to delete an infectious contact. Each cycle of
the chain thus contains 32 updating events. To improve mixing
every 50th cycle the positions in the digraph of infected persons
(both vaccinated and vaccinated) are randomly permuted so that
the chain does not get stuck in topologies from which links to
persons with unknown infection status cannot easily be removed.
Notice that this operation leaves the topology of the graph intact
(distribution of links and types), and thus does not affect the
likelihood.
After running a number of exploratory analyses output is
generated for a single chain of length 30,000–50,000, of which the
last 20,000–25,000 cycles are used to obtain a thinned sample of
size 5,000 or 10,000. Inspection of convergence of the chain is
performed visually. Run times are approximately 7–10 days on a
3.2Ghz eight-core workstation.
Simulated outbreaks
To explore the correspondence between the parameter
estimates with the data, we simulated outbreaks in schools of size
200 using the digraph construction described above. To prevent
early extinction we introduced three infectious persons with
random vaccination status in each simulation. For each vaccina-
tion composition, we generated 5,000 random digraphs with the
values of the basic reproduction number and vaccine efficacy
sampled without replacement from the posterior distribution.
Subsequently, for each graph we calculated the attack rate among
those that were initially susceptible, and present the median and
2.5% and 97.5% percentiles of the resulting distributions (the
black line and grey area in Figure 2).
Estimation of vaccine efficacy by the cohort method
To compare our results with estimates of vaccine efficacy using
the cohort method [14], we have calculated vaccine efficacy as
1 minus the relative risk of infection in vaccinated versus
unvaccinated persons. In these analyses only information of
persons with known vaccination and infection status was taken into
account (Table S1). As in the above we employ a Bayesian
framework in which the probabilities in the unvaccinated and
vaccinated groups are assigned uniform prior distributions,
yielding beta-binomial posterior distributions for the infection
probabilities. Estimates are obtained using Markov chain Monte
Carlo (MCMC) methods, specifically by taking a thinned sample
of 10,000 from a converged chain of length 500,000. Table S3
reports classical (frequentist) estimates of vaccine efficacy using the
cohort method [14].
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